Maintenance or Consolidation Therapy in Advanced Ovarian Cancer
Authors:
- D. PectasidesDPD. Pectasides
- E. PectasidesEPE. Pectasides
- 1 January 2006
- journal article
- review article
- Published by S. Karger AG in Oncology
- Vol. 70 (5) , 315-324
Abstract
Most patients with advanced epithelial ovarian cancer (EOC) achieve a clinical complete response (CR) or have no clinical evidence of disease after aggressive cytoreductive surgery and 6 cycles of platinum-/taxane-based chemotherapy. From the reported randomized trials using different durations or different cycles of chemotherapy, none of these showed improvement in survival beyond 6 cycles. Data from the literature do not support a relationship between the number of cycles and response or between the cumulative dose and response. In addition, no benefit in survival was detected with high-dose and intensity chemotherapy administered for a short time compared with standard-dose chemotherapy given for a longer time. However, statistically significant differences in progression-free survival were found in patients who achieved a clinically defined CR to a platinum (CDDP)-/paclitaxel-based chemotherapy and who continued single-agent paclitaxel for an extended time period. Notably, this randomized trial most likely did not offer any survival advantage, as it was closed prematurely by the Data Safety Monitoring Committee in accordance with the guidelines planned for interim analysis of primary end-points.Keywords
This publication has 32 references indexed in Scilit:
- Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 2004
- Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized StudyJournal of Clinical Oncology, 2004
- Maintenance Therapy in Advanced Ovarian Cancer: Progression-Free Survival and Clinical BenefitJournal of Clinical Oncology, 2003
- Maybe More Is BetterJournal of Clinical Oncology, 2003
- Chemotherapy and AntiangiogenesisActa Oncologica, 2003
- Tamoxifen Therapy for Ovarian Cancer in the Adjuvant and Advanced Settings: Systematic Review of the Literature and Implications for Future ResearchGynecologic Oncology, 2002
- Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women with Stage III Epithelial Ovarian Cancer: A Southwest Oncology Group Trial (SWOG-9326)Gynecologic Oncology, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- Whole Abdominal Radiotherapy Following Second-Look Laparotomy for Ovarian CarcinomaGynecologic Oncology, 1999
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996